Novartis Institutes for BioMedical Research
LIK066
Clinical Trial Protocol CLIK066B2202 / [STUDY_ID_REMOVED]
An open -label, par allel-group study to assess the effect of 
LIK066 on urinary glucose excretion, pharmacokinetics, 
safety and tolerability
 follow ing multiple dose 
administration in patients w ith decreased renal function 
compared to subjects w ith normal renal function
Document type: Clinical Trial Protocol
EUDRACT number: 2016 -004770 -18
Version number: v00 (Original P rotocol)
Clinical Trial Phase: II
Release date: 11-Jan-2017
Property of Novartis
Confidential
May not be used, divulged, published, or otherwise disclosed
without the consent of Novartis

Novartis Confidential Page 2
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
Site Operations Manual (SOM)
A Site Operations Manual (SOM) accompanies this protocol, providing the operation al details 
for study  conduct. Note: The SOM will not be part of the Clinical Study  Report.
Notification of serious adverse events
Dear Investigator,
You must report a serious adverse event (SAE) (initial or follow -up) to Novartis as 
summarized below. Refer to Section 9.2of the protocol for SAE criteria and additional 
requirements.  See also page 2 of the SOM for further details 
on the method of reporting a 
SAE.
Complete SAE report
Submit SAE report within 24 hours after awareness of the SAE
Notify  the Novartis Medical Lead
The contact information are provided in the SOM . 

Novartis Confidential Page 3
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
Table of contents
Site Operations Manual (SOM)........................................................................................... 2
Notification of serious adverse events ................................................................................. 2
Table of contents ................................................................................................................. 3
List of tables ........................................................................................................................ 6
List of figures ...................................................................................................................... 6
List of abbreviations ............................................................................................................ 7
Pharmacokinetic definitions and sy mbols ........................................................................... 9
Glossary  of terms ............................................................................................................... 10
Protocol sy nopsis ............................................................................................................... 12
1Introduction ....................................................................................................................... 16
1.1 Background ............................................................................................................ 17
17
18
18
18
19
20
1.4 Study  purpose ........................................................................................................ 20
2Study  objectives and endpoints ......................................................................................... 20
2.1 Primary  objectives ................................................................................................. 20
2.2 Secondary  objective ............................................................................................... 21
21
3Investigational plan ........................................................................................................... 22
3.1 Study  design ........................................................................................................... 22
3.2 Rationale of study  design ....................................................................................... 24
24
3.4 Rationale for choice of comparator ....................................................................... 24
3.5 Purpose and timing of interim anal yses/design adaptations .................................. 25
25
3.6.1 Blood sample volumes .......................................................................... 26
4Population .......................................................................................................................... 26
4.1 Inclusion criteria .................................................................................................... 26
4.1.1 All individuals ....................................................................................... 26
4.1.2 Patients with decreased renal function .................................................. 27
4.1.3 Subjects with normal renal function ..................................................... 27

Novartis Confidential Page 4
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
4.2 Exclusion criteria ................................................................................................... 28
4.2.1 All individuals ....................................................................................... 28
4.2.2 Patients wi th decreased renal function .................................................. 30
4.2.3 Subjects with normal renal function ..................................................... 31
5Restrictions for Study  Subjects ......................................................................................... 31
5.1 Contraception requirements ................................................................................... 31
5.2 Prohibited treatment ............................................................................................... 31
5.3 Dietary  restrictions and smoking ........................................................................... 31
5.4 Other restrictions ................................................................................................... 32
6Treatment ........................................................................................................................... 32
6.1 Study  treatment ...................................................................................................... 32
6.2 Treatment arms ...................................................................................................... 32
6.3 Treatment assignment ............................................................................................ 32
6.4 Treatment blinding ................................................................................................. 32
6.5 Treating the subject ................................................................................................ 33
6.6 Permitted dose adjustments and interruptions of study  treatment ......................... 33
6.7 Emergency  breaking of a ssigned treatment code .................................................. 33
6.8 Treatment exposure and compliance ..................................................................... 33
6.9 Recommended treatment of adverse events .......................................................... 33
6.10 Rescue medication................................................................................................. 33
6.11 Concomitant treatment ........................................................................................... 33
7Study  completion and discontinuation .............................................................................. 34
7.1 Study  completion and post -study  treatment .......................................................... 34
7.2 Discontinuation of study  treatment ........................................................................ 34
7.3 Withdrawal of informed consent ........................................................................... 35
7.4 Lost to follow -up ................................................................................................... 36
7.5 Study  Stopping rules .............................................................................................. 36
7.6 Early study termination by the sponsor ................................................................. 36
8 Procedures and assessments .............................................................................................. 37
37
8.2 Informed consent procedures................................................................................. 41
8.3 Subject screening................................................................................................... 41
8.4 Subject demographics/other baseline characteristics............................................. 41
8.5 Efficacy  / Pharmacod ynamics ............................................................................... 42
8.6 Safet y ..................................................................................................................... 42
8.7 Pharmacokinetics ................................................................................................... 43

Novartis Confidential Page 5
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
44
44
9Safet y monitoring .............................................................................................................. 44
9.1 Adverse events ....................................................................................................... 44
9.2 Serious adverse event reporting ............................................................................. 46
9.2.1 Definition of SAE ................................................................................. 46
9.2.2 SAE reporting ........................................................................................ 47
9.3 Liver safety  monitoring ......................................................................................... 48
9.4 Renal safet y monitoring ......................................................................................... 49
49
49
9.7 Monitoring ketoacidosis ........................................................................................ 49
9.8 Reporting Medication errors including misuse/abuse ........................................... 50
9.9 Pregnancy  reporting ............................................................................................... 50
9.10 Early phase safet y monitoring ............................................................................... 50
10Data review and database management ............................................................................. 51
10.1 Site monitoring ...................................................................................................... 51
10.2 Data collection....................................................................................................... 51
10.3 Database management and quality  control ............................................................ 52
10.4 Data Monitoring Committee .................................................................................. 52
10.5 Adjudication Committee ........................................................................................ 52
11Data analy sis...................................................................................................................... 53
11.1 Analy sis sets .......................................................................................................... 53
11.2 Subject demographics and other baseline characteristics...................................... 53
11.3 Treatments ............................................................................................................. 53
11.4 Analy sis of the primary  variable(s) ....................................................................... 53
11.4.1 Variable(s) ............................................................................................. 53
11.4.2 Statistical model, hy pothesis, and method of analysis .......................... 54
11.4.3 Handling of missing values/censoring/discontinuations ....................... 54
11.4.4 Summary  statistics of phar macokinetics ............................................... 55
11.4.5 Sensitivity  anal yses............................................................................... 55
11.5 Analy sis of second ary variable(s) .......................................................................... 55
11.5.1 Efficacy  / Pharmacod ynamics ............................................................... 55
11.5.2 Safety..................................................................................................... 55
11.5.3 Pharmacokinetic / pharmacod ynamic interactions ................................ 56
57

Novartis Confidential Page 6
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
11.7 Sample size calculation.......................................................................................... 58
11.8 Power for anal ysis of key secondary  variables ...................................................... 58
11.9 Interim anal yses..................................................................................................... 58
12 Ethical considerations........................................................................................................ 59
12.1 Regulatory and ethical compliance ........................................................................ 59
12.2 Responsibilities of the investigator and IRB/IEC .................................................. 59
12.3 Publication of study  protocol and results ............................................................... 59
13Protocol adherence ............................................................................................................ 59
13.1 Protocol Amendments ........................................................................................... 60
14References ......................................................................................................................... 61
15Appendix 1: L iver Event Definitions and Follow -up Requirements ................................. 62
16 Appendix 2: Specific Renal Alert Criteria and Actions .................................................... 64
List of tables
Table 1 -1 Summary  of plasma PK parameters following multiple dose 
administration of LIK066 to healthy su bjects ....................................... 19
37
Table 15 -1 Liver Event Definitions......................................................................... 62
Table 15 -2 Actions required for Liver Events ......................................................... 62
Table 15 -3 Exclusion of underly ing liver disease ................................................... 63
Table 16 -1 Specific Renal A lert Criteria and Actions ............................................. 64
Table 16 -2 Follow- up of renal events ...................................................................... 65
List of figures
Figure 3 -1 Study  design .......................................................................................... 22

Novartis Confidential Page 7
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
List of abbreviations
γ-GT gamma -glutam yl transferase
AE adverse event
ALP alkaline phosphatase
ALT alanine aminotransferase
ANCOVA analysis of covariance
AST aspartate aminotransferase
b.i.d. twice a day
BMI body  mass i ndex
BUN blood urea nitrogen
CFR Code of Federal Regulation
CK creatinine kinase
CRF Case Report/Record Form (paper or electronic)
CRO Contract Research Organization
CTRD Clinical Trial Results Database
CV coefficient of variation
EC Ethics Committee
ECG electrocardiogram
EDxx effective dose xx%
EDC electronic data c apture
eGFR estimated glomerular filtration rate
ELISA enzyme-linked immunosorbent assay
FDA Food and Drug Administration
GCP Good Clinical Practice
h hour
HIV Human Immunodeficiency  Virus
i.v. intravenous
ICHInternational Conference on Harmonization of Technical Requirements for 
Registration of Pharmaceuticals for Human Use
IEC Independent Ethics Committee
IRB Institutional Review Board
LC- liquid chromatograph y-mass spectrometry /mass spectrometry

Novartis Confidential Page 8
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
MS/MS
LDH lactate deh ydrogenase
LFT liver function test
LLN lower limit of normal
LLOQ lower limit of quantification
MDRD Modification of Diet in Renal Disease Study equation
MedDRA medical dictionary  for regulatory  activities
MI myocardial infarction
NCDS Novartis Clinical Data Standards
NOEL no observed effect level
p.o. oral
PD pharmacod ynamic(s)
PK pharmacokinetic(s)
RBC red blood cell(s)
REB Research Ethics Board
RI renal impairment
SAE serious adverse event
SCr serum creatinine
SD standard deviation
SGLT sodium glucose co -transporter
SGOT serum glutamic oxaloacetic transaminase
SGPT serum glutamic p yruvic transaminase
SOM Site Operations Manual
SUSAR Suspected Unexpected Serious Adverse Reactions
T2DM type 2 diabetes mellitus
TBL total bilirubin
UGE urinary  glucose excretion
ULN upper limit of normal
ULOQ upper limit of quantification
WBC white blood cell(s)
WHO World Health Organization

Novartis Confidential Page 9
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
Pharmacokinetic definitions and sy mbols
Ae0-tAmount of drug (or defined metabolite) excreted into the urine from time 
zero to time 't' where t is a defined time point after administration [mass 
units or % of dose]
AUCinfThe area under the plasma concentration -time curve from time zero to 
infinity  [mass x time / volume]
AUClastThe area under the plasma concentration -time curve from time zero to the 
time of the last quantifiable concentration [mass x time / volume]
AUCtauThe area under the plasma concentration -time curve from time zero to the 
end of the dosing interval tau [mass x time / volume]
CL/FThe apparent systemic (or total body ) clearance from plasma (or serum or 
blood) following extravascular administration [volume / tim e]
CLr The renal clearance from plasma [volume / time]
CmaxThe observed maximum plasma concentration following drug administration 
[mass / volume]
F Bioavailabilit y of a compound. 
T1/2 The terminal elimination half -life [time]
TmaxThe time to reach the maximum concentration after drug administration 
[time]
Vz/FThe apparent volume of distribution during the terminal elimination phase 
following extravascular administration [volume]

Novartis Confidential Page 10
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
Glossary  of terms
Assessment A procedure used to generate data required b y the study
Cohort A specific group of subjects fulfilling certain criteria
DosageDose of the study  treatment given to the subject in a time unit (e.g. 100 
mg once a day , 75 mg twice a day )
EnrollmentPoint/time of subject entry  into the study  at which informed consent 
must be obtained (i.e. prior to starting any of the procedures described 
in the protocol)
EpochInterval of time in the planned conduct of a study . An epoch is 
associated with a purpose (e.g. screening, treatment, follow -up) which 
applies across all arms of a study .
Health y volunteerA person with no known significant health problems who volunteers to 
be a stud y participant 
Investigational drugThe study  drug whose properties are being tested in the study ; this 
definition is consistent with US CFR 21 Section 312.3 and Directive 
2001/20/EC and is synony mous with “investigational new drug” or 
“test substance”
Patient An individual with the condition of interest
PeriodA minor subdivision of the study  timeline; divides phases into smaller 
functional segments such as screening, baseline, titration, washout, etc.
Premature subject 
withdrawalPoint/time when the subject exits from the study  prior to the planned 
completion of all study  drug administration and assessments; at this 
time all study  drug administration is discontinued and no further 
assessments are planned.
Screen Failure A subject who is screened but is not treated
StageA major subdivision of the study  timeline; begins and ends with major 
study  milestones suc h as enrollment, completion of treatment, etc.
Study  completionPoint/time at which the subject came in for a final evaluation visit or 
when study  drug was discontinued whichever is later.
Study  drug 
discontinuationPoint/time when subject permanentl y stops taking study  drug for any 
reason; may or may not also be the point/time of premature subject 
withdrawal.
Study  
drug/treatmentAny drug (or combination of drugs) administered to the subject as part 
of the required study  procedures; includes investiga tional drug, active 
drug run -ins or background therapy .
Study  treatmentAny drug administered to the study  participants as part of the required 
study  procedures; includes investigational drug (s), control(s) or non-
investigational medicinal product(s)

Novartis Confidential Page 11
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
Study  treatment 
discontinuationWhen the subject permanently  stops taking study treatment prior to the 
defined stud y treatment completion date
Subject A trial participant (can be a healthy  volunteer or a patient)
Subject numberA unique number assigned to each subject upon signing the informed 
consent. This number is the definitive, unique identifier for the subject 
and should be used to identify  the subject throughout the study  for all 
data collected, sample labels, etc.
Treatment numberA unique identi fier assigned in non-randomized studies to each dosed 
subject, corresponding to a specific treatment arm 
VariableA measured value or assessed response that is determined in specific 
assessments and used in data analysis to evaluate the drug being tested
in the study
Withdrawal of 
consent (WoC)Withdrawal of consent from the study  is defined as when a subject 
does not want to participate in the study  any longer, anddoes not want 
any further visits or assessments, anddoes not want any further study 
related contact, and does not allow analy sis of alread y obtained 
biologic material

Novartis Confidential Page 12
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
Protocol sy nopsis
Protocol number CLIK066B2202
Title An open -label, parallel-group study  to assess theeffect of LIK066 on urinary 
glucose excretion, pharmacokinetics, safety and tolerability following multiple 
dose administration in patients with decreased renal function compared to 
subjects with normal renal function
Brief title Study of pharmacodynamics, pharm acokinetics, safety and tolerability  of 
LIK066 in patients with d ecreased renal function
Sponsor and Clinical 
Trial PhaseNovartis
Phase II
Intervention type Investigational Drug
Study type Interventional
Purpose and 
rationaleThe purpose of this study is: 1) to determine whether LIK066 displays a
similar effect on the urinary   glucose excretion in patients with varying 
degrees of reduced renal function as those with normal renal function, and 2) 
to assess the pharmacokinetics of LIK066 in patients with varying degrees of 
renal impairm ent as compar ed to those with normal renal function; to support 
development of LIK066 in patients with renal impairment
Primary ObjectivesTo assess the effect of a 7 -day treatment with LIK066 on 24 -hour urinar y 
glucose excretion in subjects with decreased renal funct ion compared to 
those with normal renal function.
To assess the pharmacokinetics of LIK066 on Day 1 and Day 7 in 
subjects with decreased renal function compared to those with normal 
renal function.
Secondary ObjectiveTo assess the safety  and tolerability of a 7 -day treatment with LIK066 in 
subjects with decreased renal function compared to those with normal 
renal function.
Study design An open -label, multiple-dose, parallel -group study  in patients with varying 
degrees of decreased renal function (mild, moderate and severe renal 
impairm ent) and subjects with normal renal function. Each subject will 
participate in a screening period of up to 28 days, one baseline period, one 
treatment period of 7 days (including domicile and outpatient visits), a follow -
up period, and an end -of-study evaluation approximately  96 hours after the 
last drug administration.
Eligible subjects will be admitted to the study  site at Baseline (Day  -2). 
Meal contents including carbohy drates and salt will be standardized from 
Day-2 to the morning of Day 2, and then from Day 5 to Day 8,  
 
. LIK066 treatment will be administered once daily after an overnight 
fast, before breakfast from Day  1 to Day 7.Subjects can be dom iciled during 
the study per the investigator discretion.   The study assessments will include 
24-hour urine collection and blood collections for pharmacokinetic, 
pharmacodynamics, safety 
 
Study com pletion evaluations will be performed after the last pharmacokinetic 
assessment is completed (Day 11), or in the case of early termination, prior 
to discharge from the study site.

Novartis Confidential Page 13
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
Population Ten (10) subjects each with mild (eGFR 60-89 ml/min/1.73 m2), Grade A 
moderate (eGFR 46-59 ml/min/1.73 m2),Grade B moderate (eGFR 30-45 
ml/min/1.73 m2), and normal renal function (eGFR ≥90 ml/min/1.73 m2); and 
up to 10 patients with severe renal impairment (eGFR ≤29 ml/min/1.73 m2, 
not on dialysis) will be enrolled in this study.
Patients with varying degrees of decreased renal function will be enrolled 
first; subjects with normal renal function will be enrolled after approximately 
50% of the patients with decreased renal function (at least two in each group 
of patients with moderate renal impairm ent, and at least one patient in the 
group of patients with severe renal impairm ent) have been enrolled. The 10
subjects with normal renal function will be matched to 10 of the enrolled 
patients with decreased renal function by age, weight, and, if possible, 
diabetic status.
Key Inclusion 
criteriaAll individuals:
Male and female subjects age 18 to 78 years, inclu sive, with BMI 
≤50kg/m 2andwith controlled health condition as determined by past 
medical histor y, physical examination, electrocardiogram, and laboratory 
tests at screening.
For patients with T ype 2 diabetes, HbAc1<10% at screening. If treated 
with ant idiabetic medications (other than prohibited medications), 
patients must be on a stable dose for approximately 6 weeks prior to 
starting the study treatment and maintain the dose until the end of the 
study.
Patients with decreased renal function:
Patients must have stable renal disease without evidence of active 
progression at screening (for the purpose of this study stable renal 
disease will be defined as no significant change of eGFR for 12 weeks, 
per the discretion of the investigator upon reviewing the medical history 
or previous lab assessments). 
Mild renal impairment: eGFR from 60 to 89 ml/min/1.73 m2
Grade A moderate renal impairment: eGFR from 46 to 59 
ml/min/1.73 m 2
Grade B moderate renal impairment: eGFR from 30 to 45 
ml/min/1.73 m 2
Severe renal impairment: eGFR of ≤29 ml/min/1.73 m 2, not on 
dialysis
Subjects with normal renal function:
Normal renal function reflected by an eGFR of  ≥90 ml/min/1.73m 2.
Subjects will be matched to 10 of the enrolled patients with decreased 
renal funct ion by age (approximately ± 10 years), weight (approximately 
± 20%), and, if possible, diabetic status.

Novartis Confidential Page 14
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
Key Exclusion 
criteriaAll individuals:
Pregnant or nursing (lactating) women. Women of child -bearing potential, 
unless they are using basic methods of contraception during the study.
Patients with type 1 diabetes, or histor y of acute diabetic complications 
such as ketoacidosis or hyperosmolar state (coma) within the 6 months 
prior to screening.
Evidence of urinary obstruction or difficulty in voiding at screening
Symptomatic genital or urinary tract infection (UTI) in the 4 weeks prior to 
screening or the presence of active UTI at screening
Any finding during screening assessments (physical examination, vital 
signs, ECG or clinical lab assessments), surg ical or medical condition 
which might significantly alter the absorption, distribution, metabolism, or 
excretion of drugs, or which may  jeopardize the subject, per the 
investigator’s judgment, in case of participation in the study.
Clinically significant G I disorder related to malabsorption or GI surger y 
that may affect drug or glucose absorption (e.g. swallowing disorder, 
severe GI motility disorder, chronic diarrhea, glucose/galactose/lactose 
intolerance)
Use of prohibited medications
Patients with decrea sed renal function:
Hemoglobin levels <8.0 g/dl at screening
Subjects with normal renal function:
Hemoglobin levels <12.0 g/dl for males, or <11.0 g/dl for females at 
screening
Study treatment The investigational drug, LIK066 tablets will be prepared by Novartis. This is 
an open label nonrandomized study . All subjects will receive LIK066 50 mg 
once daily before breakfast for 7 days.
Efficacy/PD 
assessmentsUrinar y glucose excretion
Key safety 
assessmentsPhysical examination
Body tem perature
Hematology
Blood chemistry
Urinalysis
Blood pressure
Pulse rate
ECG evaluation
Adverse events and serious adverse events

Novartis Confidential Page 15
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
Data analysis The primary  analyses will assess the effect of reduced renal function on 
24-hour urinary glucose excretion (UGE24 )and on the PK of LIK066. 
Thechange from baseline in UGE24 will be analy zed using ananaly sis of 
covariance model with diabetic status, renal impaired group, day, and all 
associated interactions (where possible) asfixed factors and age, baseline 
body  weight, and baseline fasting plasma glucose as covariates . Each of the 
log-transformed PK parameters will be analyzed using the same model but 
without the baseline covariates.
Key words Decreased renal function. Urinar y gluco se excretion. Pharmacokinetics 

Novartis Confidential Page 16
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
1 Introduction
Obesity  has become a major global health problem that contributes causall y to and 
exacerbates many serious co-morbidities including hypertension, dyslipidemia, and 
importantly  type 2 diabetes (T2DM). In contrast to the numerous medicines that are available 
to treat these obesity -related diseases, relativel y few agents are available for the treatment of 
obesity  itself that are effective, safe or scalable to the size of the affected population 
(Morgen andSorensen 2014 ). Anovel mechanism to lower body  weight is via inhibition of 
the sodium glucose co-transporters 1 and 2 (SGLTs) resulting in inhibition of the glucose 
absorption in the gut and reabsorption in the kidney  (Chao and Henry  2010). In health y 
subjects, virtually  all of the filtered glucose is reabsorbed into the circulation and no glucose 
is detected in the urine. SGLT2 located in the segments 1 and 2 of the proximal tubule 
contributes to~90% of reabsorption of the filtered glucose (Abdul -Ghani et al 2015 ). SGLT1 
is located in the more distal part of the proximal tubule, segment 3, and contributes to the 
remaining ~10% of filtered glucose. However, when SGLT2 is inhibited 
with empagliflozin 
(a SGLT2 inhibitor), SGTL 1 compensates for the reabsorption of filtered glucose and SGLT1 
is capable of reabsorbing >40% of filtered glucose load in a mouse model 
(Abdul -Ghani et al 2015 ). In addition to expression in the kidney , SGLT1 is also expressed in 
the small intestine, where it is required for glucose and galactose absorption. Inhibition of 
enteric SGLT1 results in glucose and galactose malabsorption ( Turk e t al 1991 ), which results 
in calorie wasting and other potential endocrine -based weight loss mechanisms.
LIK066 is a potent dual inhibitor of SGLT1/2, which has been studied in healthy  subjects, 
patients with T2DM, and obe se patients with elevated BMI. LIK066 is generall y safe and well 
tolerated in the clinical studies being completed to date. LIK066 has a favorable 
pharmacokinetic profile (T1/2 of 10
-16 hours), which allows once daily dosing. LIK066 at 
150 mg daily dose (as qd, bid or tid) results in a significant weight loss in obese patients; 
~6% decrease in body  weight was demonstrated after 12 week treatment.
All selective SGLT2 inhibitors being approved in the clinical practice are either not 
recommended or contraindicated in patients with moderate or severe renal impairment 
(either eGFR<60; or eGFR<45 mL/min) primarily  due to lack of effic acy and certain safet y 
concerns . Dual inhibition of SGLT1 and SGLT2 leads to further caloric wasting of glucose 
attributed to reduced absorption of glucose from the intestine and enhanced inhibition of 
glucose reabsorption from the kidney s, which is a major mechanistic differentiation from a 
selective SGLT2 inhibitor. This study  is designed to assess the potential efficacy  of LIK066 in 
patients with moderate or severe chronic kidney  disease using 24-hour urinary  glucose 
excretion (UGE 24)as the primary  surrogate endpoint. The design of this study  will also 
evaluate the PK of LIK066 in patients with reduced renal function. Safet y and tolerability  of 
LIK066 at 50 mg qdfor 7 days will also be assessed in this patient population with reduced 
renal function.

Novartis Confidential Page 17
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
1.1 Background
The most relevant data for the present study are summar ized in the sections below. 
Fordetailed information, please refer to the Investigator's Brochure.

Novartis Confidential Page 18
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202

Novartis Confidential Page 19
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202

Novartis Confidential Page 20
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
1.4 Stud y purpose
The purpose of this study is: 1) to determine whether LIK066 display s a similar effect on the 
urinary  glucose excretion in patients with varying degrees of reduced renal function as those 
with normal renal function, and 2) to assess the pharmacokinetics of LIK066 in patients with 
varying degrees of renal impairment as compared tothose with normal renal function; to 
support development of LIK066 in patients with kidney  disease.
2 Study  objectives and endpoints
2.1 Primary  objective s
Primary objectives Endpoints related to primary objectives
To assess the effect of a 7- day treatment with 
LIK066 on 24 -hour urinary  glucose excretion 
(UGE) in subjects with decreased renal function 
compared to those with normal renal function24-hour urinary  glucose excretion 
on Day  7
To assess the pharmacokinetics of LIK066 on 
Day 1 and Day  7 in subject s with decreased 
renal function compared to those with normal 
renal function Cmax, Tmax, AUCtau, AUClast, 
AUCinf, T1/2, CL /F, Vz/F, CLr

Novartis Confidential Page 21
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
2.2 Secondary  objective
Secondary objective Endpoints related to secondary objective
To assess the safety  and tolerability  of a 7-
day treatment with LIK066 in subjects with 
decreased renal function compared to those 
with normal renal function  Adverse events

Novartis Confidential Page 22
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
3 Investigational plan
3.1 Stud y design
This study  employ s an open -label, multiple -dose, parallel -group desig n in patients with 
varying degrees of decreased renal function (mild, moderate and severe renal impairment) and 
subje cts with normal renal function. The most common cause of chronic kidney  disease is 
diabetes, which accounts for roughl y 50% of all cases. Approximately  50% of the patients 
enrolled in each group of the mild, moderate and severe renal impairment are expected to be 
patients with T2DM .  
Each subject will participate in a screening period of up to 28days, one baseline period, 
onetreatment period of 7 days (including domicile and outpatient visits), a follow -up period, 
and an end -of-study  evaluation approximately  96 hours after the last drug administration.
Ten (10) subjects each with mild (eGFR 60-89 ml/min/1.73 m2), Grade A moderate 
(eGFR 46-59 ml/min/1.73 m2), Grade B moderate (eGFR 30-45 ml /min/1.73 m2), and normal 
renal function (eGFR ≥90 ml/min/1.73 m2); and up to 10 patients with severe renal impairment 
(eGFR ≤29 ml/min/1.73 m2, not on dialy sis) will be enrolled.
Figure 3-1 Study  design
Patients with varying degrees of decreased renal function will be enrolled first; subjects with 
normal renal function will be enrolled after approximately  50% of the patients with decreased 
renal function (at least two in each group of patients with moderate renal impairment, and at 
least one patient in the group of patients with severe renal impairment) have been enrolled. 
Because body  weight and age are covariates in the estimation of eGFR formula, the 
10subjects with normal renal function will be matched to 10 of the enrolled patients with 

Novartis Confidential Page 23
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
decreased renal function by age (approximately  ± 10 years), weight (approximately  ± 20%), 
and, if possible, diabetic status. The 10 patients with decreased renal function on whom the 
matching will be based will be selected so as to cover as broad age range as possible. 
Theenrolled patients will be ranked by age and selected, beginning with the youngest and 
ending with the oldest, in an increment that yields 10 total patients. Efforts will be made to 
match the diabetic status, where possible, to ensure representation of both diabetic and non -
diabetic populations in the group of subjects with normal renal function.
The renal function (eGFR) will be assessed based on the MDRD equation (Leve yet al 2006 ) 
during the screening visit. The MDRD equation (Serum creatinine levels in mg/dl) to be used 
is as follows:
eGFR = 175 x Serum Creatinine-1.154x Age-0.203x [1.212 if Black] x [0.742 if Female]
Additional details about the eGFR equations and the standardized creatinine assay s will be 
provided in the SOM . 
Each subject will attend Screening visit(s) when the inclusion/exclusion criteria will be 
assessed. Eligible subjects will be admitted to the study  site at Baseline (Day  -2), where 
eligibility  for enrollment into the study  will be confirmed as needed. All baseline safety 
evaluation results must be available and reviewed prior to dosing when screeni ng is 
performed more than 7 days prior to dosing.  Each subject will receive once daily  LIK066 at 
50 mg dose for 7 days.  Meal contents including carboh ydrates and salt will be standardized 
from Day -2 to the morning of Day 2, and then from Day 5 to Day 8,  
 Detailed information on 
meal recomme ndation is provided in the SOM. Baseline twent y-four hour urine samples will 
be collected. Study  participants must be fasted for approximately  10 hours before Day 1 
dosing of LIK066. Standardized breakfast will be provided immediately  after the 
administration of LIK066 in the morning. 
Following the first dose on Day 1, subjects will remain domiciled for at least 24 hours for 
collection of urine and blood samples for urinary  glucose excretion, pharmacokinetic, 
pharmacod ynamic and safet y assessments. Subjects will either remain domiciled 
(mandatory for subjects with severe renal impairment) or return in the morning to the study 
site every  day (Day 3  to Day 5) to receive their medication after approximately  10 -hour 
fasting overnight, per the investigator discretion as described in the SOM. A standardized 
breakfast will be served immediately  after administration of LIK066 every day. Subjects will 
be domiciled from Day 5 and will be fasted for approximately  10 hours before the final dose 
on the morning of Day 7 at the site. Subjects will remain domiciled up to Day 8 to complete 
24-hour collection of urine and blood for urinary  glucos e excretion, pharmacokinetic, 
pharmacod ynamic and safet y assessments after the final dose. Blood and urine samples for 
pharmacokinetic assessments will be taken on Days 9, 10 and 11 (up to 96 hours post the final 
dose). Study  completion evaluations will beperformed after the last pharmacokinetic 
assessment is completed (Day  11), or in the case of early termination, prior to discharge from 
the study  site.
Safet y assessments will include physical examinations, ECGs, vital signs, standard clinical 
laboratory  evaluations (blood chemistry , urinaly sis, hematology ), and adverse event and 
serious adverse event monitoring. See the assessment schedule for further details.

Novartis Confidential Page 24
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
3.2 Rationale of study  design
The design of this study  addresses the primary  objective of assessing the effects of LIK066 on 
urinary  glucose excretion and the pharmacokinetics of LIK066 in subjects with reduced renal 
function as compared to those with normal renal function. The 24-hour urinary  glucose 
excretion (UGE24) is zero in healthy  subjects and ~10 g in patients with T2DM in the absence 
of a SGLT inhibitor such as LIK066. The UGE24 is ~100 g when LIK066 is given to patients 
with T2DM, therefore, the diabetic status is expected to have little impact on the assessment 
of UGE24. In addition, the assess ment of UGE24 will be based on the changes corrected by 
baseline UGE24. The matching of subjects with normal renal function to a subset of the 
subjects with reduced renal function will be done to minimize bias in the comparison due to 
confounding factors of age, body  weight, and diabetic status. An open -label design without a 
placebo comparator is appropriate as the primary  endpoints, 24 -hour urinary  glucose excretion 
and pharmacokinetics, are objective parameters.   
3.4 Rationale for choice of comparator
Not applicable.

Novartis Confidential Page 25
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
3.5 Purpose and timing of interim analy ses/design adaptations
An interim analy sis may be initiated once approximately  half of the enrolled subjects have 
completed the study . The purpose of the analy sis will be to assess the impact of reduced renal 
function on UGE24 in order to inform developmen t decisions for LIK066. Actions such as 
early termination of the study  should ob jectives be met, adjustments to the sample size, and/or 
revisions of the dose may be made. Additional interim analy ses may be conducted to support 
decision making concerning the current clinical study , the sponsor’s clinical development 
projects in general or in case of any safet y concerns. The clinical team may communicate 
interim results to relevant Novartis teams for information, consulting and/or decision purposes.

Novartis Confidential Page 26
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
3.6.1 Blood sample volumes
Approximately  up to 200 mL of blood is planned to be collected from each subject over 2 -3 
weeks during the study . Additional samples for monitoring of any safet y findings would be in 
addition to this. This is not considered to be a risk for this population.
Timings of blood sample collection are outlined in the Assessment Schedule, Section 8.1 .
A summary  blood log is provided in the SOM , together with instructions for all sample 
collection, processing, storage and shipment information.
See Section 8.9 regarding the potential use of residual samples. 
4 Population
4.1 Inclusion criteria
4.1.1 All individuals
Subjects with normal and decreased renal function eligible for inclusion in this study  must 
fulfill allof the following criteria:
1.Written informed consent must be obtained before any  assessment is performed.
2.Male and female subjects age 18 to 78 years, inclusive, wi th controlled health condition as 
determined b y past medical history, ph ysical examination, electrocardiogram, and 
laboratory  tests at screening.
3.For patients with Ty pe 2 diabetes, HbAc1<10% at screening.
4. If treated with antidiabetic medications (other tha n prohibited medications), patients must 
be on a stable dose for approximately  6 weeks prior to starting the study  treatment and 
maintain the dose until the end of the stud y.
5.Body mass index (BMI) ≤50 kg/m2at Screening.
6.Able to communicate well with the I nvestigator, to understand and comply with the 
requirements of the study.

Novartis Confidential Page 27
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
4.1.2 Patients with decreased renal function
7.Patients must have stable renal disease at screening without evidence of active progression 
(for the purpose of this study  stable renal disease will be defined as no significant change 
of eGFR for 12 weeks, per the discretion of the investigator upon reviewing the medical 
history  or previous lab assessments).
Mild renal impairment: eGFR from 60 to 89 ml/min/1.73 m2
Grade A moderate renal impairmen t: eGFR from 46 to 59 ml/min/1.73 m2
Grade B moderate renal impairment: eGFR from 30 to 45 ml/min/1.73 m2
Severe renal impairment: eGFR of ≤29 ml/min/1.73 m2, not on dialy sis
8. Vital signs (after 3 minutes resting measured in the supine position). The Investigator 
should be guided b y the following ranges:
oral body temperature between 35.0 -37.8 °C
systolic blood pressure, 100 -180 mm Hg
diastolic blood pressure, 50- 110 mm Hg
pulse rate, 45 -100 bpm
Blood pressure and pulse will be taken again in a standing position. After 3 minutes standing, 
there shall be no more than a 20 mm Hg drop in sy stolic or 10 mm Hg drop in diastolic blood 
pressure associated wi th clinical manifestation of symptomatic postural hypotension.
4.1.3 Subjects with normal renal function
9.Except for the medical conditions allowed in the inclusion/exclusion criteria (e.g. diabetes 
or hypertension), no other significant medical conditions at screeni ngor baseline as 
determined b y medical history  and ph ysicalexamination .
10.Normal renal function reflected b y an eGFR of ≥90 ml/min/1.73m2.
11. Vital signs (after 3 minutes resting measured in the supine position).  The Investigator 
should be guided b y the following ranges:
oral body temperature between 35.0 -37.2°C
systolic blood pressure, 100 -150 mm Hg
diastolic blood pressure, 60- 100 mm Hg
pulse rate, 45 -100 bpm
Blood pressure and pulse will be taken again in a standing position. After 3 minutes standing, 
there shall be no more than a 20 mm Hg drop in sy stolic or 10 mm Hg drop in diastolic blood 
pressure associated with clinical manifestation of no sy mptomatic postural hy potension.
12.Subjects will be matched to 10 of the enrolled patients with decreased renal function by  
age (approximately  ± 10 y ears), weight (approximately  ± 20%), and, if possible, diabet ic 
status.

Novartis Confidential Page 28
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
4.2 Exclusion criteria
4.2.1 All individuals
Subjects with normal and decreased renal function fulfilling any of the following criteria are 
noteligible for inclusion in this study :
1.Pregnant or nursing (lactating) women, where pregnancy  is defined as the state of a female 
after conception and until the termination of gestation, confirmed by  a positive hCG 
laboratory  test.
2.Women of child -bearing potential, defined as all women phy siolo gically  capable of 
becoming pregnant, unless they  are using basic methods of contraception during the study . 
Basic contraception methods include:
Total abstinence when this is in line with the preferred and usual lifest yle of the 
subject. Periodic abstinen ce (i.e., calendar, ovulation, sy mptothermal, post- ovulation 
methods) and withdrawal are not acceptable methods of contraception
Female sterilization (have had surgical bilateral oophorectom y (with or without 
hysterectomy)), total h ysterectom y or tubal lig ation at least six weeks before taking 
study  treatment. In case of oophorectom y alone, only  when the reproductive status of 
the woman has been confirmed by  follow -up hormone level assessment
Male sterilization (at least 6 m prior to screening). The vasecto mized male partner 
should be the sole partner for that subject.
Barrier methods of contraception: Condom or Occlusive cap. For UK: with 
spermicidal foam/gel/film/cream/vaginal suppository
Use of oral, injected or implanted hormonal methods of contraception or other forms 
of hormonal contraception that have comparable efficacy  (failure rate <1%), for 
example hormone vaginal ring or transdermal hormone contraception or placement of 
an intrauterine device (IUD) or intrauterine s ystem (IUS)
In case of use of or al contraception , women should have been stable on the same pill for a 
minimum of 3 months before taking stud y treatment.
Women are considered post -menopausal and not of child bearing potential if they  have 
had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile 
(e.g. age appropriate, history  of vasomotor s ymptoms) or have had surgical bilateral 
oophorectom y (with or without hy sterectomy ) or tubal ligation (hy sterectomy  is 
acceptable) at least six weeks ago. In the case of oop horectom y alone, onl y when the 
reproductive status of the woman has been confirmed by  follow -up hormone level 
assessment is she considered not of child bearing potential.
3.Patients with type 1 diabetes, or history  of acute diabetic complications such as 
ketoacidosis or h yperosmolar state (coma) within the 6 months prior to screening .
4.Evidence of clinicall y significant  abnormal liver function tests for an y of the labs at 
screening, confirmed b y a repeat measure within 7 day s :
ALT, AST, γ-GT, alkaline phosph atase > 3 x UL N.
serum bilirubin > 1.5 x ULN .
5.Evidence of urinary  obstruction or dif ficult y in voiding at screening.

Novartis Confidential Page 29
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
6.Symptomatic genital or urinary  tract infection (UTI) in the 4 weeks prior to the first study  
visit or the presence of active UTI at screeni ng.
7.Evidence or medical history  of clinicall y significant ECG abnormalities.
8.Any of the following within 6 months of screening:
myocardial infarction (MI)
coronary  artery  bypass surgery , balloon angioplasty , coronary  stent(s) in situ
unstable angina
peripheral arterial disease
congestive heart failure NYHA class II-IV
9.History  of autonomic dy sfunction (e.g. history  of fainting, clinicall y significant orthostatic 
hypotension, clinically  significant sinus arrhy thmia).
10.Significant blood loss equaling at least one unit of blood (500 ml) or a blood transfusion 
within 3 months prior to screening .
11.Evidence of immunodeficiency  diseases, including a positive HIV (ELISA and Western 
blot) test result at screening .
12.History  of drug or alcohol abuse within the 12 mo nths prior to dosing or evidence of such 
abuse as indicated b y the laboratory assays conducted during the screening or tests 
conducted during baseline evaluations .
13.Malignancy  including leukemia and l ymphoma (not including basal cell skin cancer which 
has n ot been adequatel y treated) within 5 y ears prior to screening .
14.Any finding during screening assessments (phy sical examination, vital signs, ECG or 
clinical lab assessments), surgical or medical condition which might significantly  alter the 
absorption, dist ribution, metabolism, or excretion of drugs, or which may jeopardize the 
subject, in the investigator’s judgment, in case of participation in the study .
15.Patients undergoing an y method of dialy sis (hemodialy sis or peritoneal dialy sis).
16.History  of hypersensi tivity  to the study  drug, or to drugs of similar chemical classes.
17.Clinically  significant GI disorder related to malabsorption or that may  affect drug or 
glucose absorption (e.g. swallowing disorder, severe GI motility  disorder, chronic diarrhea, 
glucose/g alactose/lactose intolerance) .
18.History  of significant gastrointestinal surgery  that could affect intestinal glucose 
absorption (e.g. bariatric surgeries including, Roux en Y gastric b ypass, sleeve 
gastrectom y, Nissen fundoplication) .
19.Subjects who experienced ketoacidosis, lactic acidosis, or hy perosmolar coma within 6 
months of Screening Visit, or between Screening Visit and Baseline Day  -1.

Novartis Confidential Page 30
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
20.Use of prohibited medications:
Use of SGLT2 or alpha -glucosidase inhibitors within 2 weeks prior to dosing and 
during the study . If treated with other oral antidiabetic medications, patients must be 
on a stable regimen for at least 6 weeks prior to starting the study  treatment
Use of potassium -binders within 3 day s prior to dosing and during the study
Treatment with drug s that have a high incidence of diarrhea during the study
Chronic sy stemic steroid treatment or s ystemic steroids for > 7 consecutive day s for 
worsening of an underl ying condition within 4 weeks of screening. Use of topical or 
inhaled steroids is permitted
Strong inhibitors of CYP3A4/5 including boceprevir, clarithrom ycin, conivaptan, 
grapefruit juice, indinavir, itraconazole, ketoconazole, lopinavir, nefazodone, 
nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithrom ycin, and 
voriconazole wi thin 7 day s prior to the study  treatment and during the study
Strong CYP3A inducers including avasimibe, carbamazepine, phen ytoin, rifampin, St. 
John’s wort within 7 day s prior to the study  treatment and during the study
General UGT inhibitors including probenecid, valproic acid within 7 day s prior to the 
study  treatment and during the stud y
Use of other investigational drugs at the time of enr ollment, or within 30 day s or 
5half-lives of starting the study  treatment or longer if required by  local regulations. 
Any other limitation of participation in an investigational trial based on local 
regulations
Use of an y medications that are contraindicated in patients with renal impairment
Use of an y drugs with known toxicity  to a major organ s ystem w ithin the pas t 
3months (i.e., cytostatic drugs) 
Unless allowed b y the study  protocol, use of an y other prescription drugs, new herbal 
supplements, within four (4) weeks prior to initial dosing, and/or over -the-counter 
(OTC) medication, new dietary  supplements (vitami ns included), within 3 day s prior 
to initial dosing. If needed, acetaminophen or ibuprofen is acceptable for incidental 
and limited use .
Such medications must be documented in the Concomitant medications / significant non-
drug therapies page of the CRF.
4.2.2 Patients with decreased renal function
Patients with decreased renal function fulfilling any of the following criteria are noteligible 
for inclusion in this study :
21.Hemoglobin levels <8.0 g/dl at screening.

Novartis Confidential Page 31
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
4.2.3 Subjects with normal renal function
Subjects with normal renal function fulfilling any  of the following criteria are noteligible for 
inclusion in this study :
22. Hemoglobin levels <12.0 g/dl for males, or <11.0 g/dl for females at screening.
No additional exclusions may be applied by the invest igator, in order to ensure that the study  
population will be representative of all eligible patients.
5 Restrictions for Study  Subjects
During recruitment, screening/informed consent review, and baseline visit, the subjects must 
be informed and reminded of t he restrictions outlined in this section.
5.1 Contraception requirements
Please refer to exclusion criteria ( Section 4.2 ) for details of contraception requirements for the study .
5.2 Prohibited treatment
Please refer to the exclusion criteria (Section 4.2 ). Subjects may  need to discontinue the study 
treatment if treated with any of the prohibited medications during the study . Concomitant and prior 
medications (dose, regimen, indication and treatment duration) must be recorded in the CRF .
5.3 Dietary  restrictions and smoking
 
No alcohol for approximately  24 hours before the study  visits until the Study  Completion 
evaluation.
No cigarettes/use of nicotine products for 8 hours before certain visits as noted in the 
SOM.
No grapefruit or grapefruit juice is to be consume d for approximately  7 days prior to 
dosing until 7 day s following the last dose. 
In order to avoid wide variations in urine volumes on UGE and PK collection day s, 
subjects should be encouraged to have a fluid intake of approximately  240 mL  every  
4hours d uring their waking hours, in addition to the fluid taken with meals and 
medication.
While domiciled, patients will follow a standard diet or a diet recommended for patients with 
kidney  disease with the following guidelines.
Approximately  2,200 calories dai ly, adjusted by  body  weight; ~50% from carbohy drates, 
~30% from fat and ~20% from protein, with consistent and within recommended amounts 
of sodium, potassium, calcium and phosphorus, and free access to water.
Identical meals should be served on day s (Base line: Day  -1 to Day  1; Treatment: Day  7 to 
Day 8) when 24 hour PD endpoints (UGE24, electroly tes and ) are 
assessed.

Novartis Confidential Page 32
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
No food other than that specified in the protocol and the SOM will be consumed during 
confinement.  
A meal record will confirm timing and consumption of meal. A copy of the diet with content 
and nutritional information (amount of protein, sodium, carboh ydrates, fat and calories for 
each meal) will be provided to the Sponsor upon request.
5.4 Other restrictions
No strenuous physical exercise (e.g. weight training, aerobics, football) for 3 days before 
dosing until after Stud y Completion evaluation s.
6 Treatment
6.1 Stud y treatment
The investigational drug, LIK066 tablets, will be prepared by Novartis and supplied to the 
Investigato r as open labeled bulk medication. No control drugs will be used in this study .
Details on the requirements for storage and management of study  treatment, and instructions 
to be followed for subject numbering, prescribing/dispensing and taking study  treatm ent are 
outlined in the SOM .
6.2 Treatment arms
This is an open label nonrandomized study . Subjects will be assigned to one of the following 
5 treatment arms according to their disease status. All subjects will receive LIK066 50 mg qd 
before breakfast for 7 da ys.
Group 1 (n=10, mild renal impairment)
Group 2 (n=10, moderate renal impairment grade A)
Group 3 (n=10, moderate renal impairment grade B)
Group 4 (n= up to 10, severe renal impairment)
Group 5 (n=10, subjects with normal renal function)
6.3 Treatment assignment
The Subject number assigned to a subject at screening remains the unique identifier for the 
subject throughout the study .Treatment numbers will be assigned in ascending, sequential 
order to eligible subjects according to the disease status as described in the SOM. The 
investigator will enter the treatment number on the (e)CRF.
If a subject requires a replacement, the replacement subject will be assigned a treatment 
number corresponding to the original number (e.g. Subject 6103 would replace Subj ect 5103).  
Any additional subjects enrolled will use sequential subject numbering.
6.4 Treatment blinding
This is an open label non -randomized study .

Novartis Confidential Page 33
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
6.5 Treating the subject
LIK066 will be administered to the subject orally  at the investigator site. See the SOM for 
further details
6.6 Permitted dose adjustments and interruptions of study  treatment
Study  treatment dose adjustments and/or interruptions are not permitted. 
For patients who are unable to tolerate the protocol -specified dosing scheme, treatment should 
be discontinued. These changes must be recorded on the Dosage Administration Record CRF.
6.7 Emergency  breaking of assigned treatment code
Not applicable as t his is an open label study . 
6.8 Treatment exposure and compliance
Study  medication will be given at the site by study  personal during domiciling or patients will 
return to the investigator site on a daily  basis during the study . PK parameters (measures of 
treatment exposure) will be determined in all patients treated with LIK066, ensuring treatment 
exposure and compliance .
6.9 Recommended treatment of adverse events
Based on prior clinical experience with LIK066, which was administered to more than 
200subjects at doses up to 350 mg single dose or up to 150 mg for 12 weeks, LIK066 -related 
AEs can be managed by clinical monitoring including vital signs and blood tests. If diarrhea 
occurs, it can be treated with oral rehy dration therapy if needed. More aggressive treatment, if 
required, will be performed at the discretion and direction of the investigator, with timely 
communication with the sponsor. Stopping rules (Section 7.4 ) will be applied as appropriate. 
Medication used to treat AEs must be recorded on the Concomitant medications/Significant 
non-drug therapies CRF.
6.10 Rescue medica tion
This is not a therapeutic study .  Rescue medication use is not allowed.
Use of medications other than the study  drug during the study  must be recorded on the 
Concomitant medications/Significant non -drug therapies CRF.
6.11 Concomitant treatment
Patients with T2DM on antidiabetic medications (other than prohibited medications) are 
allowed to participate in the study  if they are on a stable dose for at least 6 weeks prior to 
dosing and maintain the dose until the end of the study .
Antihy pertensive, dyslipid emia and GERD medications are allowed but patients must be on a 
stable regimen for 3 months or more prior to dosing and maintain the dose until the end of the 
study .
Aspirin and antianginal medications (other than ranolazine) are allowed.

Novartis Confidential Page 34
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
The investigator must instruct the subject to notify  the study  site about any new medications 
he/she takes after the subject was enrolled into the study .
All prescription medications, over-the-counter drugs and significant non-drug therapies 
(including physical therapy  andblood transfusions) administered or taken within the 
timeframe defined in the entry criteria prior to the start of the study  and during the study , must 
be recorded on the Concomitant medications/Significant non- drug therapies CRF.
Medication entries shoul d be specific to trade name, the single dose and unit, the frequenc y 
and route of administration, the start and discontinuation date and the reason for therapy .
Each concomitant drug must be individually  assessed against all exclusion criteria/prohibited 
medication. If in doubt, the investigator should contact Novartis before enrolling a subject or, 
if the subject is alread y enrolled, to determine if the subject should continue participation in 
the study .
7 Study  completion and discontinuation
7.1 Stud y completion and post -stud y treatment
Each subject will be required to complete the study  in its entirety  and thereafter no further 
study  treatment will be made available to them.
Study  completion is defined as when the last subject completes their Study  Completion visit, 
and any repeat assessments associated with this visit have been documented and followed -up 
appropriatel y by the Investigator, or in the event of an early study termination decision, the 
date of that decision.
7.2 Discontinuation of study  treatment
Discontinuation of study  treatment for a subject occurs when study  treatment is stopped 
earlier than the protocol planned duration. Discontinuation of study  treatment can be decided 
by either the subject or the investigator.
Study  treatment must be discontinued under the following circumstances:
Subject decision -subjects may  choose to discontinue study  treatment for any  reason at 
any time.
The investigator believes th at continuation would negativel y impact the safety of the 
subject or the risk/benefit ratio of trial participation.
Any protocol deviation that results in a significant risk to the subject’s safety .
Pregnancy  
Use of prohibited treatments.

Novartis Confidential Page 35
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
Study  treatment of individual subject will be placed on hold and, based on full review of the 
clinical data and discussion with the investigator, discontinuation of study  treatment may 
occur when that subject experiences:
 
 
 
 
 
Clinically  significant urinary  tract or genitourinary  infections, at the discretion of the 
investigator and consult with the sponsor if deemed necessary .
Clinically  symptomatic hy pogly cemia confirmed by  repeated blood glucose levels 
(<56 mg/dL).
Ketoacidosis (s ymptoms of ketoacidosis include nausea, vomiting, abdominal pain, 
unusual tiredness and trouble breathing). 
Any laboratory  abnormalities that in the judgment of the investigator, taking into 
consideration the subject’s overall status, prevents the subject from continuing 
participation in the study .
Any hospitalization, or other SAE, that is suspected to be related to the study  treatment.
If discontinuation of study  treatment occurs, investigator must determine the primary  reason 
for the subject’s premature discontinuation of study  treatment and record thisinformation on 
the Dosage Administration CRF.
Subjects who discontinue study  treatment or who decide they do not wish to participate in the 
study  further should NOT be considered withdrawn from the study  UNLESS they  withdraw 
their consent. Where possible, they should return for the assessments indicated by an asterisk 
(*) in the assessment table. If they fail to return for these assessments for unknown reasons, 
every  effort (e.g. telephone, e-mail, letter) should be made to contact the 
subject/pre -designat ed contact. This contact should preferably  be done according to the study  
visit schedule.
7.3 Withdrawal of informed consent
Subjects may  voluntarily  withdraw consent to participate in the study  for any  reason at any  time.
Withdrawal of consent from the study  is defined as when a subject:
Does not want to participate in the study  anymore and
Does not want an y further visits or assessments and
Does not want an y further study  related contacts and
Does not allow anal ysis of already  obtained biologic material.
In this situation, the investigator must make every  effort (e.g. telephone, e-mail, letter) to 
determine the primary  reason for the subject’s decision to withdraw his/her consent and 
record this information.

Novartis Confidential Page 36
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
Study  treatment must be discontinued and no further assessments conducted, and the data that 
would have been collected at subsequent visits will be considered missing.
Further attempts to contact the subject are not allowed unless safety  findings require 
communicating or follow -up.
7.4 Lost to follow -up
For su bjects whose status is unclear because they  fail to appear for study  visits without stating 
an intention to discontinue or withdraw, the investigator should show "due diligence" by 
documenting in the source documents steps taken to contact the subject, e.g. dates of 
telephone calls, registered letters, etc. A subject cannot be formally  considered lost to follow -
up until his/her scheduled end of study  visit would have occurred.
7.5 Stud y Stopping rules
The principal investigator and the sponsor will continually  review adverse events and 
laboratory  findings throughout the study . The study  will be placed on hold and based on full 
review of the clinical data and discussion with the investigator may be halted if the principal 
investigator and the sponsor consider tha t the number and/or severity  of adverse events justify 
discontinuation of the study ;including cumulative cases of clinicall y significant diarrhea, 
urinary  tract infections, severe adverse events, clinically  significant laboratory  changes 
suspected to be related to the study  drug, or serious adverse event ssuspected to be related to 
the study  drug.
7.6 Early study  termination by  the sponsor
The study  can be terminated by  Novartis at any  time for any  reason. This may  include reasons 
related to the benefit/ risk assessment of participating in the study, practical reasons 
(including slow enrollment), or for regulatory  or medical reasons. Should this be necessary , 
subjects must be seen as soon as possible and treated as a prematurel y withdrawn subject. 
Theinvestiga tor may be informed of additional procedures to be followed in order to ensure 
that adequate consideration is given to the protection of the subject’s interests. 
Theinvestigator will be responsible for informing IRBs/IECs of the early  termination of the 
trial.

Novartis Confidential Page 37
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
8 Procedures and assessments

Novartis Confidential Page 38
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202

Novartis Confidential Page 39
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202

Novartis Confidential Page 40
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202

Novartis Confidential Page 41
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
8.2 Informed consent procedures
Eligible subjects may only be included in the study  after providing written (witnessed, where 
required b y law or regulation), I RB/IEC -approved informed consent.
Novartis will provide to investigators a proposed informed consent form that complies with 
the ICHE6 GCP guideline and regulatory  requirements and is considered appropriate for this 
study . The informed consent form will also include a section related to optional future 
research which will require a separate signature if the subject agrees to future research.  
Any changes to the proposed consent form suggested by  the investigator must be agreed to b y 
Novartis before submission to the I RB/IEC.
Information about common side effects alread y known about the 
investigational drug can be 
found in the Investigator's Brochure (IB). This information will be included in the subject 
informed consent and should be discussed with the subject during the study  as needed. 
Any new information regarding the safet y profile of the investigational drug that is identified 
between IB updates will be communicated as appropriate, for example, via an Investigator 
Notification or an Aggregate Safet y Finding. New information might require an update to the 
informed consent and then must be discussed with the subject.
Ensure subjects are informed of the contraception requirements outlined in the Section 4.2
(Exclusion criteria) and in Section 5.1 (Contraception requirements).
 
 
 
 
A copy  of the approved version of all consent forms must be provided to the Novartis monitor 
after IRB/IEC approval.
8.3 Subject screening
In general it is permissible to re-screen a subject if s/he fails the initial screening; however, 
each case must be discussed and agreed with the Sponsor on a case-by-case basis. 
Information on what data should be collected for screening failures is outlined in the SOM .
8.4 Subject demographics/other baseline characteristics
Subject demographic and baseline characteristic data will be collected on all subjects.
Relevant medical history /current medical conditions data includes data until signature of 
informed consent. Where possible, diagnoses and not sy mptoms should be recorded.
Patients will be tested for substances of abuse (e.g., alcohol, amphetamines, barbiturates, 
benzodiazepines, cannabinoids, cocaine, and opiates), hepatitis B and C and HIV as noted in 
the Assessment schedule . Results will be available as Source data and will not be recorded 
within the eCRF.

Novartis Confidential Page 42
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
Investigators have the discretion to record abnormal test findings on the medical history  CRF 
whenever in their judgment, the test abnormality  occurred prior to the informed consent signature .
8.5 Efficacy  / Pharmacody namics
Urinary  glucose excretion (UGE) is the primary pharmacod ynamic (PD) endpoint in this 
study . PD samples will be obtained and evaluated in all subjects. PD samples will be collected 
at the time points defined in the Assessment schedule, Section 8.1. Follow instructions 
outlined in the SOM regarding sample collection, numbering, processing and shipment
.
8.6 Safet y
Safet y assessments are specified below; methods for assessment and recording are specified in 
the SOM , with the Assessment Schedule ( Section 8.1) detailing when each assessment is to be 
performed.
Physical examination
Vital signs
Body temperature
Blood pressure (BP)
Pulse
Height and weight
Height
Body weight
Body mass index 
(BMI) will be calculated (Bod y weight (kg) / [Height (m)]2)
Laboratory  evaluations
Clinically  relevant deviations of laboratory  test results occurring during or at completion of 
the study  must be reported and discussed with Novartis personnel. The results should be 
evaluated for criteria defining an adverse event and reported as such if the criteria are met. 
Repeated evaluations are mandatory  until normalization of the result(s) or until the change is 
no longer clinicall y relevant. In case of doubt, Novarti s personnel should again be contacted.
Hematology
Hemoglobin, hematocrit, red blood cell count, white blood cell count with differential and 
platelet count will be measured.
Clinical chemistry
Albumin, alkaline phosphatase, AST, ALT, total bilirubin, bicar bonate/CO 2, chloride, 
creatinine, CK, γ-GT, glucose, LDH, inorganic phosphorus, lipase, amylase, calcium, 
magnesium, potassium,  sodium, cholesterol (including total cholesterol, HDL -C and LDL -C), 
triglycerides, total protein, BUN and uric acid.

Novartis Confidential Page 43
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
If the total bilirubin concentration is increased above 2 times the upper limit of normal, direct 
and indirect reacting bilirubin should be differentiated.
Urinaly sis
Urine test by dipstick e.g. Combur9: leucocy tes, nitrite, pH, protein, glucose, ketones, 
urobilinog en, bilirubin, blood/hemoglobin
If the dipstick result is positive for protein, nitrite, leucocy tes and/or blood, the sample will be 
sent for microscopic analysis of WBC, RBC and casts.
Electrocardiogram (ECG)
PR interval, QRS duration, heart rate, RR, QT, QTc.
The Fridericia QT correction formula (QTcF) should be used for clinical decisions
8.7 Pharmacokinetics
PK samples will be obtained and evaluated in all subjects. PK samples will be collected at the 
timepoints defined in the Assessment schedule, Section 8.1. Follow instructions outlined in 
the SOM regarding sample collection, numbering, processing and shipment. See Section 8.9
regarding the potential use of residual samples.
Plasma samples will be assay ed for LIK066 concentratio ns by Novartis or a designated CRO 
using validated liquid chromatograph y
-tandem mass spectrometry assay s (LC-MS/MS). 
Themethod will have an LLOQ of at least 5 ng/mL for LIK066. 
Concentrations will be expressed in mass per volume units and will refer to LIK066 plasma 
concentrations.
 
 
 
The following plasma pharmacokinetic parameters will be determined using the actual 
recorded sampling times and non-compartmenta l method(s) with Phoenix WinNonlin 
(Version 6.2 or higher), as applicable:
Cmax, Tmax, AUClast, AUCtau, AUCinf, T1/2, CL/F, Vz/F ,as relevant ,from the plasma 
concentration -time data.

Novartis Confidential Page 44
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
Additional PK parameters (Racc, T1/2acc, Cmin,ss, Cav,ss, Tlast, Clast etc.) may be 
calculated or reported as appropriate. The linear trapezoidal rule will be used for AUC 
calculation.
The total amount of LIK066 excreted into urine (Ae0 -t) will be used to calculate the renal 
clearance (CLr) of LIK066 based on both plasma and urine data if the data allows.
Plasma sample will be collected for protein binding analysis in order to determine the 
unbound fraction of LIK066. Accordingl y, unbound PK parameters [AUC,u and Cmax,u ] 
may be calculated.
9 Safety  monitoring
9.1 Adverse events
An adverse event (AE) is any untoward medical occurrence (i.e., any unfavorable and 
unintended sign [including abnormal laboratory  findings], sy mptom or disease) in a subject or 
clinical investigation subject after providing written informed consent for participation in the 
study  until the end of study  visit. Therefore, an AE may or may not be temporally  or causall y 
associated with the use of a medicinal (investigational) product.
In addition, all reports of intentional misuse and abuse of the study  treatment are also 
considered an adverse event irrespective if a clinical event has occurred. See Section 9.5 for 
an overview of the reporting requirements.

Novartis Confidential Page 45
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
The occurrence of adverse events must be sought by non-directive questioning of the subject 
at each visit during the study . Adverse events also may  be detected when they  are volunteered 
by the subject during or between visits or through physical examination finding, laboratory  
test finding, or other assessments.
Abnormal laboratory  values or test results constitute adverse events only if they fulfill at least 
one of the following criteria:
they induce clinical signs or sy mptoms,
they are considered clinically
 significant,
they require therapy .
Clinically  significant abnormal laboratory  values or test results should be identified through a 
review of values outside of normal ranges/clinically  notable ranges, significant changes from 
baseline or the previous visit, or values which are considered to be non -typical in patients with 
underl ying disease. Investigators have the responsibility  for managing the safet y of individual 
subject and identify ing adverse events. Alert ranges for liver and kidney  related events are 
included in Appendix 1 and Appendix 2 , respectively. 
Adverse events must be recorded on the Adverse Events CRF under the signs, symptoms or 
diagnosis associated with them, and accompanied by  the following information:
1.the severit y grade  
mild: usually  transient in nature and generally  not interfering with normal activities
moderate: sufficiently  discomforting to interfere wit h normal activities
severe: prevents normal activities
2.its relationship to the study  treatment  
Yes or
No
3.its duration (start and end dates) or if the event is ongoing an outcome of not 
recovered/not resolved must be reported.
4.whether it constitutes a SAE (see Section 9.2 for definition of SAE) and which seriousness 
criteria have been met  
5. Action taken regarding investigational treatment.
All adverse events must be treated appropriately. Treatment may include one or more of 
the following: 
no action taken (e.g. further observation only )
investigational treatment dosage increased/reduced
investigational treatment interrupted/withdrawn
concomitant medication or non- drug therap y given
hospitalization/prolonged hospitalization (see Section 9.2 for definition of SAE)
6.its outcome (not recovered/not resolved; recovered/resolved; recovering/resolving, 
recovered/resolved with sequelae; fatal; or unknown). .

Novartis Confidential Page 46
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
Information about common side effects alread y known about the investigational drug can be 
found in the Investigator's Brochure (IB).  Once an adverse event is detected, it must be 
followed until its resolution or until it is judged to be permanent, and assessment should be 
made at each visit (or more frequentl y, if necessary ) of any changes in severity , the suspected 
relationship to the investigational drug, the interventions required to treat it, and the outcome.
The investigator must also instruct each subject to report any new adverse event (beyond the 
protocol observation period) that the subject, or the subject’s personal physician, believes 
might reasonabl y be related to study  treatment. This information must be recorded in the 
investigator’s source documents; however, if the AE meets the criteria of an SAE, it must be 
reported to Novartis.
9.2 Serious adverse event reporting
9.2.1 Definition of SA E
An SAE is defined as any adverse event (appearance of (or worsening of any pre-existing) 
undesirable sign(s), symptom(s) or medical conditions(s)) which meets any one of the 
following criteria:
is fatal or life -threatening
results in persistent or significant disability /incapacity
constitutes a congenital anomaly /birth defect
requires inpatient hospitalization or prolongation of existing hospitalization, unless 
hospitalization is for: 
routine treatment or monitoring of the existing condition, not associated with any  
deterioration in condition 
elective or pre -planned treatment for a pre -existing condition that has not worsened 
since the start of stud y drug
treatment on an emergency  outpatient basis for an event not fulfilling any  of the 
definitions of a SAE given above and not resulting in hospital admission
social reasons and respite care in the absence of any  deterioration in the subject’s 
general condition
is medically  significant, e.g. defined as an event that jeopardizes the subject or may  
require medical or surgical intervention.
All malignant neoplasms will be assessed as serious under “medically  significant” if other 
seriousness criteria are not met.
Life-threatening in the context of a SAE refers to a reaction in which the subject was at risk of 
death at the time of the reaction; it does not refer to a reaction that hypothetically  might have 
caused death if it were more severe (see Annex I V, ICH-E2D Guidel ine).
Medical and scientific judgment should be exercised in deciding whether other situations 
should be considered serious reactions, such as important medical events that might not be 
immediately  life threatening or result in death or hospitalization butmight jeopardize the 
subject or might require intervention to prevent one of the other outcomes listed above. 
Examples of such events are intensive treatment in an emergency  room or at home for allergic 

Novartis Confidential Page 47
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization or 
development of dependency
 or abuse (see Annex IV, ICH-E2D Guideline).
Any suspected transmission via a medicinal product of an infectious agent is also considered a 
serious adverse reaction.
All AEs (serious and non-serious) are captured on the CRF; SAEs also require individual reporting 
to Novartis Chief Medical Office and Patient Safety  (CMO& PS) as per Section 9.2.2.
9.2.2 SAE reporting
To ensure subject safet y, every  SAE, regardless of causali ty, occurring after the subject has 
provided informed consent and until 30 days after the last study  visit must be reported to 
Novartis within 24 hours of learning of its occurrence as described below. Any SAEs 
experienced after this period should only be reported to Novartis if the investigator suspects a 
causal relationship to study  treatment.
Note: SAEs reported by subjects deemed to be screen failures are only collected from time 
sign ICF until when subject is deemed a screen failure ,with appropriate information also 
captured in the CRFs as specified in the SOM .
All follow -up information for the SAE including information on complications, progression of 
the initial SAE and recurrent episodes must be reported as follow -up to the original episode 
within 24 hours of the investigator receiving the follow - up information. An SAE occurring at 
a different time interval or otherwise considered completely  unrelated to a previously  reported 
one must be reported separatel y as a new event.
Follow -up information provided must describe whether the event has resolved or contin ues, if 
and how it was treated and whether the subject continued or withdrew from study 
participation. Each re-occurrence, complication, or progression of the original event must be 
reported as a follow -up to that event regardless of when it occurs.
If the SAE is not previously  documented in the Investigator’s Brochure and is thought to be 
related to the study  treatment a Chief Medical Office and Patient Safety  Department associate 
may urgently require further information from the investigator for Health Authority  reporting. 
Novartis may need to issue an Investigator Notification (IN) to inform all investigators 
involved in any study  with the same study  treatment that this SAE has been reported. 
Suspected Unexpected Serious Adverse Reactions (SUSARs) will be collected and reported to 
the competent authorities and relevant ethics committees in accordance with EU Guidance 
2011/C 172/01 or as per national regulatory  requirements in participating countries.
Follow the detailed instructions outlined in the SOM regarding the submission process for 
repor ting SAEs to Novartis.   Note: SAEs must be reported to Novartis within 24 hours of 
the investigator learning of its occurrence/receiving follow -up inform ation.

Novartis Confidential Page 48
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
9.3 Liver safety  monitoring
To ensure subject safety  and enhance reliability  in determining the hepatotoxic potential of an 
investigational drug, a standardized process for identification, monitoring and evaluation of 
liver events has to be followed.
Please refer to Table 15 -1-Appendix 1 for complete definitions of liver events.
Follow -up of liver events
Every  liver event defined in Table 15 -
1-Appendix 1 should be followed up by  the inv estigator 
or designated personnel at the trial site, as summarized below. Additional details on actions 
required in case of liver events are outlined in Table 15 -2-Appendix 1 . 
Repeating liver chemistry tests (ALT, AS T, TBL, PT/I NR, ALP and γ -
GT) to confirm 
elevation within 48- 72 hours.  
These liver chemistry  repeats should be performed using the local laboratory used b y the 
site. Repeat laboratory  test results must be reported as appropriate via an electronic data 
transfer (if applicable) .  
If the initial elevation is confirmed, close observation of the subject will be initiated, 
including consideration of treatment interruption if deemed appropriate.
Discontinuation of the investigational drug (refer to Section 7.2 (Discontinuation of study  
treatment), if appropriate
Hospitalization of the subject if appropriate
Causality  assessment of the liver event
Thorough follow -up of the liver event should include: 
Repeating liver chemistry tests two or three times weekl y. Testing should incl ude 
ALT, AST, AL P, PT/INR, and γ-GT. If total bilirubin is elevated > 2 x ULN, 
fractionation into direct and indirect bilirubin is required. To rule out muscular origin 
of transaminase elevations, CPK should be measured along with liver chemistry  tests. 
Frequency  of retesting can decrease to once a week or less if abnormali ties stabilize 
or the study  drug has been discontinued and the subject is asy mptomatic. Retesting 
should be continued up to resolution. 
Obtaining a more detailed history  of symptoms and prior or concurrent diseases.
Obtaining a history  of concomitant drug use (including nonprescription medications 
and herbal and dietary  supplement preparations), alcohol use, recreational drug use, 
and special diets.
Exclusion of underly ing liver disease, as specified in Table 15 -3.
Imaging suc h as abdominal US, CT or MRI , as appropriate
Obtaining a history  of exposure to environmental chemical agents.
Considering gastroenterology  or hepatology  consultations.
All follow -up information, and the procedures performed must be recorded as appropriate in 
the CRF.

Novartis Confidential Page 49
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
9.4 Renal safety  monitoring
Renal events are defined as one of the following:
Confirmed (after ≥ 24h) increase in serum creatinine of ≥ 25 % compared to baseline 
during normal hy dration status, and deemed as a new onset renal events in patients wi th 
reduced renal function at the discretion of investigator(s)
A doubling in the urinary albumin- creatinine ratio (ACR) or urinary  protein -creatinine 
ratio (PCR).
New onset ( ≥1+) proteinuria or hematuria 
Every  renal event must be followed up by the investigator or designated personnel at the trial 
site. Recommended follow -up assessments are listed in Section 16- Appendix 2 .
9.7 Monitoring ketoacidosis
In rare cases, SGLT -2 inhib itors can lead to ketoacidosis. Therefore, investigators must pay 
close attention for any  signs of ketoacidosis. Signs and sy mptoms of ketoacidosis may  include 
deep and rapid breathing, nausea, vomiting, severe abdominal pain, confusion, unusual fatigue 
orsleepiness, and coma. All signs and/or symptoms and results from relevant laboratory  tests 
must be reported on the AE eCRF. If ketoacidosis is confirmed, the study  treatment should 
discontinued as per Section 7.2 and appropr iate measures must be taken to correct the acidosis
and monitor glucose levels according to standard of care.

Novartis Confidential Page 50
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
Every  case of ketoacidosis must be reported to the Ketoacidosis Adjudication Committee 
(seeSection 10.5).
9.8 Reporting Medication errors including misuse/abuse
All study  treatment errors and uses outside of what is foreseen in the protocol will be 
collected in the dose administration record (DAR) CRF.  Study  treatment errors are only  to be 
reported to Novarti
s Chief Medical Office and Patient Safet y department if the treatment error 
is associated with an SAE.
For more information on AE and SAE definition and reporting requirements, please see 
Section 9.1 and Section 9.2, respectivel y.
9.9 Pregnancy  reporting
To ensure subject safet y, each pregnancy  occurring after signing the informed consent must 
be reported to Novartis within 24 hours of learning of its occurrence. The pregnancy should 
be followed up t o determine outcome, including spontaneous or voluntary  termination, details 
of the birth, and the presence or absence of any birth defects, congenital abnormalities, or 
maternal and/or newborn complications.
Pregnancy  must be recorded on the Pharmacovigil ance Pregnancy  Form and reported by the 
investigator to the local Novartis Chief Medical Office and Patient Safet y Department. 
Pregnancy  follow -
up should be recorded on the same form and should include an assessment 
of the possible relationship to the stud y treatment.
Any SAE experienced during the pregnancy  and unrelated to the pregnancy  must be reported 
on a SAE form.
The study  drug must be discontinued, though the subject may stay in the study , if she wishes 
to do so. All assessments that are considered as a risk during pregnancy  must not be 
performed. The subject may  continue all other protocol assessments.
9.10 Earl y phase safety  monitoring
The Investigator will monitor adverse events in an ongoing manner and inform the Sponsor of 
any clinically  relevant observations. Any required safet y reviews will be made jointly 
between medicall y qualified personnel representing the Sponsor and Investigator. 
Such evaluations may occur verball y, but the outcome and key discussion points will be 
summarized in writing (e-mail) and made available to both Sponsor and all Investigator(s). 
Criteria pertaining to stopping the study /treatment or adapting the study  design are presented 
above.
When two or more clinical site(s) are participating in the clinical study, the Sponsor will 
advise the Investigator(s) at all sites in writing (e-mail) (and by telephone if possible) of any 
new, clinically  relevant safet y information reported from another site during the conduct of 
the study  in a timel y manner.

Novartis Confidential Page 51
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
10 Data revie w and database manage ment
10.1 Site monitoring
Before study  initiation, at a site initiation visit or at an investigator’s meeting, a Novartis 
representative will review the protocol and CRFs with the invest igators and their staff. 
During the study ,Novartis employ s several methods of ensuring protocol and GCP 
compliance and the quality /integrit y of the sites’ data. The monitor will visit the site to check 
the completeness of subject records, the accuracy  of entries on the CRFs, the adherence to the 
protocol and to Good Clinical Practice, the progress of enrollment, and ensure that study  drug 
is being stored, dispensed, and accounted for according to specifications. Key  study  personnel 
must be available to assist the monitor during these visits.
The investigator must maintain source documents for each subject in the study , consisting of 
case and visit notes (hospital or clinic medical records) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information on CRFs must be traceable to these source documents in the 
subject's file. The investigator must also keep the original informed consent form signed by 
the subject (a signed copy  is given to the subject).
The investigator must give the monitor access to all relevant source documents to confirm 
their consistency  with the CRF entries. Novartis monitoring standards require full verification 
for the presence of informed consent, adherence to the eligibility  criteria, documentation of 
SAEs, and the recording of data that will be used for all primary  and safet y variables. 
Additional checks of the consistency  of the source data with the CRFs are performed 
according to the study -specific monitoring plan. No information in source documents about 
the identity of the subjects will be disclosed.
10.2 Data collection
Designated investigator staff will enter the data required by the protocol into the Electronic 
Case Report Forms using fully validated software that conforms to 21 CFR Part 11 
requirements. Designated investigator site staff will not be given access to the EDC system 
until they have been trained. Validation checks for data discrepancies and, by generating 
appropriate error messages, allow the data to be confirmed or corrected before transfer of the 
data to Novartis or the CRO working on behalf of Novartis. The Investigator must certify  that 
the data entered into the Electronic Case Report Forms are complete and accurate. 
After database lock, the investigator will receive copies of the subject data for ar chiving at the 
investigational site.
Data not requiring a separate written record will be defined in the SOM and 
Assessment schedule and can be recorded directly  on the CRFs. All other data captured for
this study  will have an external originating source (either written or electronic) with the CRF 
not being considered as source.
All data should be recorded, handled and stored in a way that allows its accurate reporting, 
interpretation and verification.

Novartis Confidential Page 52
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
10.3 Database manage ment and quality  control
Novartis staff review the data entered into the CRFs by investigational staff for completeness 
and accuracy  and instruct the site personnel to make any required corrections or additions. 
Queries are sent to the investigational sitevia the EDC system . Designated investigator site 
staff is required to respond to the query  and confirm or correct the data. If the electronic query 
system is not used, a paper Data Query  Form will be faxed to the site. Site personnel will 
complete and sign the faxed copy and fax it back to Novartis staff who will make the correction to 
the database. The signed copy  of the Data Query  Form is kept at the investigator site.
Concomitant medications entered into the database will be coded using the WHO Drug 
Reference List, which employ s the Anatomical Therapeutic Chemical classification system. 
Medical history /current medical conditions and adverse events will be coded using the 
Medical dictionary  for regulatory  activities (MedDRA) terminology .
Laboratory  result s will be sent electronicall y to Novartis (or a designated CRO).
The occurrence of any protocol deviations will be determined. After these actions have been 
completed and the database has been declared to be complete and accurate, it will be locked 
and made available for data analysis. Any changes to the database after that time can only be 
made by joint written agreement between the COAR Analy tics NIBR Franchise Head and the 
relevant NIBR TA Head.
10.4 Data Monitoring Committee
Not applicable .
10.5 Adjudication Committee
An Adjudication Committee will be established to assess suspected cases of ketoacidosis as 
described in the SOM.

Novartis Confidential Page 53
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
11 Data analy sis
11.1 Analysis sets
For all anal ysis sets, subjects will be anal yzed according to the stud y treatmen t(s) received.
The safety  anal ysis set will include all subjects that received any  study  drug.
The PK analy sis set will include all subjects with at least one available valid (i.e. not flagged 
for exclusion) PK concentration measurement, who received any study drug and with no 
protocol deviations that impact on PK data.
The PD analysis set will include all subjects with available PD data and no protocol 
deviations with relevant impact on PD data.
11.2 Subject demographics and other baseline characteristics
All data for background and demographic variables will belisted by renal function 
(mild impairment, Grade A moderate impairment, Grade B moderate impairment, severe 
impairment, or normal) and subject. Summary  statistics will be provided by renal function.
Relevant medical history, current medical conditions, results of laboratory screens, drug tests 
and an y other relevant information will be listed by renal function and subject.
11.3 Treatments
Data for study  drug administration (rescue medication) and concomitant therapies will be 
listed renal function and subject.
11.4 Analysis of the primary  variable(s)
11.4.1 Variable(s)
The primary  PD endpoint will be UGE24.
The primary  PK endpoints will be the Cmax, Tmax, AUCtau, AUClast, AUCinf, T1/2, CL/F 
of LIK066.
The secondary  PK 
endpoints will be Vz/F and CLr of LIK066.

Novartis Confidential Page 54
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
11.4.2 Statistical model, hypothesis, and method of analy sis
The primary  analyses will assess the effect of reduced renal function on UGE24 and on the 
PK of LIK066.
UGE24
The change from baseline in UGE24 will be analyzedusing an analy sis of covariance 
(ANCOVA) model with diabetic status, renal impaired group, day, and all associated 
interactions (where possible) as fixed factors and age, baseline body  weight, and baseline 
fasting plasma glucose as covariates. Baseline fasting plasma glucose and baseline body 
weight will be the measurements on Day  1 0-hour. An unstructured covariance matrix will be used.
The least -square mean change from baseline will be estimated for each diabetic status by  renal 
function by day combinati on. In addition, the mean difference between each renal impaired 
group and the group with normal renal function and the corresponding two- sided 90% 
confidence interval and p-value for the difference will be extracted for each diabetic status by 
day combina tion.
UGE24 will be summarized by diabetic status, renal function, and day. The change from 
baseline and % change from baseline will also be summarized. 
The relationship between eGFR and UGE24 will be assessed graphically , separatel y by day .
PK
Each of th e log -transformed PK parameters (Cmax, AUCtau, AUClast, AUCinf as applicable) 
will be analy zed using the same model described above for UGE24 but without the baseline 
covariates. For each parameter, the least-square geometric mean will be estimated for each 
diabetic status by renal function by day combination. In addition, the geometric mean ratio of 
each renal impaired group to the group with normal renal function (expressed as a percent 
relative difference) and the corresponding two-sided 90% confidence interval and p-value for 
the ratio will be extracted for each diabetic status by day  combination.
Statistical analysis may be performed to compare the free fraction (fu) across the treatment 
groups. If statistically  significant difference exists in fu acros s treatment groups, the same 
analysis (as planned for total parameters) will also be performed to compare the AUC,u and 
Cmax,u between treatment groups.
 
Thesummary  of PK parameters is described below in Section 11.4.4.
11.4.3 Handling of missing values/censoring/discontinuations
All drug concentrations below the lower limit of quantification (LLOQ) will be reported as 
“zero” and will be treated as zero for calculation of PK parameters. No other imputation of 
missing values will be performed.

Novartis Confidential Page 55
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
11.4.4 Summary  statistics of pharmacokinetics
LIK066 plasma concentration data will be listed by  renal function, subject, and visit/sampling 
time point. Descriptive statistics will be provided by renal function and visit/sampling time 
point, including the frequency  (n, %) of concentrations below the LLOQ and reported as zero. 
Summary  statistics will include mean (arithmetic and geometric), SD, CV (arithmetic and 
geometric), median, minimum, and maximum. Concentrations below LLO Q will be treated as 
zero in the summary  statistics. A geometric mean will not be reported if the dataset includes 
zero values.
Each of the PK parameters will be listed by renal function, subject, and day and summarized 
by renal function and day . Descriptive statistics will include mean (arithmetic and geometric), 
SD, CV (arithmetic and geometric), median, minimum, and maximum. An exception to this is 
Tmax where median, minimum, and maximum will be presented.
11.4.5 Sensitivity analy ses
Two sensitivity  anal yses of UGE24 may  be performed:
(1) a similar analy sis as the primary  UGE anal ysis, except that natural logarithm of the ratio to 
baseline in UGE24 will be modeled instead of the change from baseline. For this analy sis, the 
least-square geometric mean will be estimated for each diabetic status by renal function by 
day combination, in addition to the geometric mean ratio of each renal impaired group to the 
group with normal renal function (expressed as a percent relative difference) and the 
corresponding two-sided 90% confidence interval and p-value, separately for each diabetic 
status by  day combination.
(2) the same analy sis described for the primary  UGE analysis, except that baseline UGE24 
will be used as a covariate in place of baseline fasting plasma glucose. Baseline UGE24 will 
be the collection taking place on Day -1. The same model -based quantities described for the 
primary  anal ysis will be extracted.
11.5 Analysis of secondar y variable(s)
11.5.1 Efficacy  / Pharmacodynamics
See Section 11.4.2.
11.5.2 Safety
Vital signs
All vital signs data will be listed by renal function, subject, and visit/time and if ranges are 
available abnormalities (and relevant orthostatic changes) will be flagged. Summary  statistics 
will be provided b y renal function and visit/time.
ECG evaluations
All ECG data will be listed by renal function, subject and visit/time, abnormalities will be 
flagged. Summary  statisti cs will be provided b y renal function and visit/time.

Novartis Confidential Page 56
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
Clinical laboratory  evaluations
All laboratory  data will be listed by renal function, subject, and visit/time and if normal 
ranges are available abnormalities will be flagged. Summary  statistics will beprovided by 
renal function and visit/time.
Adverse events
All information obtained on adverse events will be display ed by renal function and subject.
The number and percentage of subjects with adverse events will be tabulated by body system 
and preferred term with a breakdown by renal function. A subject with multiple adverse 
events within a bod y system is only  counted once towards the total of this body  system.
Anion gap
From measurements of sodium, chloride, and bicarbonate in serum, the anion gap will be 
derived as sodium –
(chloride + bicarbonate) and will be an additional safet y variable. 
Theanion gap and change from baseline in anion gap will be summarized by diabetic status, 
renal function, and day . 
For each subject, the maximum post-baseline value and the maximum change from baseline 
will be extracted and will be summarized by  diabetic status and renal function. 
11.5.3 Pharmacokinetic / pharmacodynamic interactions
The relationship between UGE24  and each of the 
primary  PK parameters may be assessed graphically , in addition to the relationship between 
eGFR and each of the primary  PK parameters.

Novartis Confidential Page 57
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202

Novartis Confidential Page 58
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
11.7 Sample size calculation
The sample size was chosen to provide adequate precision around the estimated mean 
difference in change from baseline UGE24 between a renal impaired group and the group of 
normal controls. 
After 7 days of treatment of LIK066 15 mg once daily  in patients with type-2 diabetes in the 
first-in-human study  LIK066X2101, the mean and standard deviation of the change from 
baseline in UGE24 was approximately  98 g and 24 g respectivel y. If we observe similar 
variability  in this study , with 10 enrolled subjects in the mild and moderate renal impaired 
groups and in the group of normal controls and at least 8 completers in each of these groups, a 
two-sided 90% CI for the differenc e of means will extend no more than 22.7 g from the 
observed difference. As an example, in the renal impairment study  for the SGL T2 inhibitor 
empagliflozin (Macha et al 2014), the observed difference between the moderate impai red 
group and the normal controls was 42 g, representing a 43% decrease in UGE24. If we see a 
similar reduction in our study , the CI for the difference would extend to no more than 19.3 g 
to 64.7 g. We consider this as adequate precision for the estimation of the difference in change 
from baseline UGE24 between the groups.
The sample size also provides adequate precision fora comparison of the primary 
PKvariables between groups. After a single dose of LIK066 50 mg in healthy  volunteers in 
LIK066X2101, thecoefficient of variation of the Cmax of LIK066 was approximately  22%. 
Assuming similar variability  in this study , with at least 8 completers in each group, a 
two-sided 90% CI for the ratio of means will have a lower bound that extends to no less than 
0.81 times the observed ratio and an upper bound to no more than 1.23 times the observed 
ratio. We consider this as adequate precision for the estimation of the ratio of Cmax between 
the groups.
11.8 Power for analy sis of key secondary  variables
Not applicable.
11.9 Interim analy ses
Refer to Section 3.5. Statistical details of the interim analysis will be described in the
Statistical Analy sis Plan (SAP).

Novartis Confidential Page 59
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
12 Ethical considerations
12.1 Regulatory  and ethical compliance
This clinical study  was designed and shall be implemented, executed and reported in 
accordance with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with 
applicable local regulations (including European Directive 2001/20/EC, US Code of Federal 
Regulations Title 21, and Japanese Ministry  of Health, Labor, and Welfare), and with the 
ethical principles laid down in the Declaration of Helsinki.
12.2 Responsibilities of the investigator and IRB/IEC
Before initiating a trial, the investigator/institution must obtain approval/favorable opinion 
from the Institutional Review Board/Independent Ethics Committee (IRB/IEC) for the trial 
protocol, written informed consent form, consent form updates, subject recruitment 
procedures (e.g. advertisements) and any other written infor mation to be provided to subjects. 
Prior to study  start, the investigator is required to sign a protocol signature page confirming 
his/her agreement to conduct the study  in accordance with these documents and all of the 
instructions and procedures found inthis protocol and to give access to all relevant data and 
records to Novartis monitors, auditors, Novartis Quality  Assurance representatives, designated 
agents of Novartis, IRBs/IECs, and regulatory  authorities as required. If an inspection of the 
clinica l site is requested by a regulatory  authority , the investigator must inform Novartis 
immediately  that this request has been made.
For multi- center trials, a Coordinating Investigator will be selected by Novartis around the 
time of Last Patient Last Visit t o be a reviewer and signatory for the clinical study report. 
12.3 Publication of study  protocol and results
The key design elements of this protocol will be posted in a publicly  accessible database such 
as clinicaltrials.gov. In addition, upon study  completion and finalization of the study  report 
the results of this trial will be either submitted for publication and/or posted in a publicl y 
accessible database of clinical trial results.
13 Protocol adherence
This protocol defines the study  objectives, the study  procedures and the data to be collected 
on study  participants. Additional assessments required to ensure safet y of subjects should be 
administered as deemed necessary  on a case by case basis. Under no circumstances is an 
investigator allowed to collect additi onal data or conduct any additional procedures for any 
research related purpose involving an y investigational drugs under the protocol.
Investigators ascertain they will apply due diligence to avoid protocol deviations. If an 
investigator feels a protocol deviation would improve the conduct of the study  this must be 
considered a protocol amendment, and unless such an amendment is agreed upon by Novartis 
and approved by the IRB/IEC and health authorities, where required, it cannot be 
implemented.

Novartis Confidential Page 60
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
13.1 Protocol Amendments
Any change to the protocol can only be made in a written protocol amendment that must be 
approved by Novartis, Health Authorities where required, and the IRB/IEC prior to 
implementation.
Amendments that are intended to eliminate an apparent imme diate hazard to subjects may be 
implemented immediately , provided the Health Authorities are subsequently  notified by 
protocol amendment and the reviewing IRB/IEC is notified.
Notwithstanding the need for approval of formal protocol amendments, the investi gator is 
expected to take any immediate action required for the safety  of any subject included in this 
study , even if this action represents a deviation from the protocol. In such cases, the reporting 
requirements identified in Section 9 (Safet y Monitoring) must be followed and the Study  Lead 
informed.

Novartis Confidential Page 61
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
14 References
Abdul -Ghani MA, Norton L , DeFronzo RA (2015) Renal sodium -glucose cotransporter 
inhibition in the management of ty pe 2 diabetes mellitus. Am . J. Phy siol. Renal Phy siol.
p.F889 -900.
Chao EC, Henry  RR (2010) SGL T2 inhibition --a novel strategy  for diabetes treatment. Nat 
Rev Drug Discov p. 551-9.
Levey  AS, Coresh J, Greene T, et al (2006) Using standardized serum creatinine values in the 
modification of diet in renal disea se study  equation for estimating glomerular filtration rate. 
Ann. Intern. Med. p. 247 -54.
Macha S, Mattheus M, Halabi A, et al (2014) Pharmacokinetics, pharmacody namics and 
safet y of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in sub jects with 
renal impairment. Diabetes Obes Metab p. 215 -22.
Morgen CS, Sørensen TI (2014) Obesit y: global trends in the prevalence of overweight and 
obesity . Nat Rev Endocrinol p. 513
-4.
Turk E, Zabel B, Mundlos S, et al (1991) Glucose/galactose malabsorpt ion caused b y a defect 
in the Na+/glucose cotransporter. Nature p. 354 -6.

Novartis Confidential Page 62
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
15 Appendix 1: Liver Event Definitions and Follo w-up 
Requirements
Table 15-1 Liver Event Definitions
Definition Thresholds
Potential Hy’s law cases ALT or AST > 3 × ULN and TBL > 2 × ULN without initial 
increase in ALP to > 2 × ULN
New onset ALT or AST elevation 
with coagulopathyALT or AST > 3 × ULN and INR > 1.5 (in the absence of 
anticoagulation)
New onset ALT or AST elevation 
accompanied by sy mptomsALT or AST > 3 × ULN accompanied by (general) malaise, 
fatigue, abdominal pain, nausea, or vomiting, or rash, or 
eosinophilia
Isolated ALT or AST elevation ALT or AST > 8 × ULN
5 x ULN < ALT/AST ≤8 x ULN
3 x ULN < ALT/AST ≤5 x ULN
Isolated ALP elevation ALP > 2 × ULN (in the absence of known bone pathology)
OthersAny clinical event of jaundice (or equivalent term)
Any adverse event potentially indicative of liver toxicity
Table 15-2 Actions required for Liver Events
Criteria Actions required
Potential Hy’s Law case
Discontinue the study treatment immediately
Hospitalize, if clinically appropriate
Establish causality
Complete CRFs per liver event guidanceNew onset ALT or AST elevation with 
coagulopathy
New onset ALT or AST elevation 
accompanied by sy mptoms
Isolated ALT or AST elevation > 8 × ULN
Jaundice
Isolated ALT or AST elevation > 5 to ≤ 8 × 
ULNIf confirmed, consider interruption or 
discontinuation of study drug
If elevation persists for more than 2 weeks, 
discontinue the study drug
Establish causality
Complete CRFs per liver event guidance
Isolated ALT or AST elevation > 3 to ≤ 5 × 
ULN (patient is asy mptomatic)Monitor liver chemistry tests two or three times 
weekly
Isolated ALP elevation Repeat liver chemistry  tests within 48 -72 hours
If elevation is confirmed, measure fractionated 
ALP; if >50% is of liver origin, establish hepatic 
causality
Complete CRFs per liver event guidance

Novartis Confidential Page 63
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
Criteria Actions required
Any AE potentially indicative of liver toxicityConsider study treatment interruption or 
discontinuation
Hospitalize if clinically appropriate
Complete CRFs per liver event guidance
Table 15-3 Exclusion of underly ing liver disease
Disease Assessment
Hepatitis A, B, C, E IgM anti -HAV; HBSAg, IgM anti -HBc, HBV DNA; anti -HCV, 
HCV RNA, IgM & IgG anti -HEV, HEV RNA
CMV, HSV, EBV infection IgM & IgG anti -CMV, IgM & IgG anti -HSV; IgM & IgG anti -
EBV
Autoimmune hepatitis ANA & ASMA titers, total IgM, IgG, IgE, IgA
Alcoholic hepatitis Ethanol history, gGT, MCV, CD- transferrin
Nonalcoholic steatohepatitis Ultrasound or MRI
Hypoxic/ischemic hepatopathy Medical histor y: acute or chronic CHF, hypotension, 
hypoxia, hepatic venous occlusion. Ultrasound or MRI.
Biliar y tract disease Ultrasound or MRI, ERCP as appropriate.
Wilson disease Caeruloplasmin
Hemochromatosis Ferritin, transferrin
Alpha -1-antitr ypsin deficiency Alpha -1-antitr ypsin

Novartis Confidential Page 64
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
16 Appendix 2: Specific Renal A lert Criteria and A ctions
Table 16-1 Specific Renal A lert Criteria and Actions
Criteria Action required
Serum creatinine (sCr) increase
25 –49% compared to baselineConsider causes and possible interventions
Follow up within 2 -5 day s
Serum creatinine increase > 50% Consider causes and possible interventions
Repeat assessment within 24 -48h if possible
Consider drug interruption or discontinuation unless 
other causes are diagnosed and corrected
Consider hospitalization and specialized treatment
Protein -creatinine or albumin -
creatinine ratio increase ≥ 2-fold
or
new onset dipstick proteinuria ≥ 1+
or
Albumin -creatinine ratio (ACR) ≥ 30 
mg/g or ≥ 3 mg/mmol;
or
Protein -creatinine ratio (PCR ) ≥ 150 
mg/g or >15 mg/mmolConsider causes and possible interventions
Assess serum albumin & serum protein
Repeat assessment to con firm
Consider drug interruption or discontinuation unless 
other causes are diagnosed and corrected
New hematuria on dipstickAssess & document:
Urine sediment microscopy
Assess sCr and urine albumin- creatinine ratio
Exclude infection, trauma, bleeding from the distal 
urinar y tract/bladder, menstruation
Consider bleeding disorder
Additional specialized assessments are available to assess renal function or renal pathology . 
(Note: In exceptional cases when a nephrologist considers a renal biopsy , it is strongl y 
recommended to make specimen slides available for evaluation by Novartis to potentiall y 
identify  project -wide patterns of nephrotoxicity .)
Whenever a renal event is identified, a detailed subject history  and examination are indicated 
to identify , document and potentiall y eliminate risk factors that may have initiated or 
contributed to the event:
Blood pressure assessment (after 5 min rest, with an appropriate cuff size)
Signs and s ymptoms such as fever, headache, shortness of breath, back or abdomi nal pain, 
dysuria, hematuria, dependent or periorbital edema
Changes in blood pressure, body  weight, fluid intake, voiding pattern, or urine output
Concomitant events or procedures such as trauma, surgical procedures, cardiac or hepatic 
failure, contrast m edia or other known nephrotoxin administration, or other potential 
causes of renal d ysfunction, e.g., dehy dration, hemorrhage, tumor l ysis

Novartis Confidential Page 65
Clinical Trial Protocol (Version No. 00) Protocol No. CLIK066B2202
Table 16-2 Follo w-up of renal even ts
Action Follow up
Assess *, document and record in the 
Case Report Form (CRF) or via 
electronic data load.Urine dipstick and sediment microscopy
Blood pressure and body weight
Serum creatinine, electrolytes (sodium, potassium, 
phosphate, calcium), bicarbonate and uric acid
Urine output
Monitor subject regularly (frequency 
at investigator’s discretion) until:Event resolution: (sCr within 10% of baseline or protein -
creatinine ratio within 50% of baseline)
or
Event stabilization: sCr level with ±10% variability over 
last 6 months or protein -creatinine ratio stabilization at a 
new level with ±50% variability over last 6 months.
* Urine osmolality: in the absence of diuretics or chronic kidney disease this can be a very sensitive 
metric for integrated kidney function that requires excellent tubular function. A high urinar y osm olality 
in the setting of an increase in sCr will point toward a “pre -renal” cause rather than tubular toxicity.
*Review and record possible contributing factors to the renal event (co-medications, other co-morbid 
conditions) and additional diagnostic procedures (MRI etc) in the CRF .
